A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by ECRI bv
Boston Scientific Corporation
Volcano Corporation
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: December 13, 2013
Last updated: September 14, 2014
Last verified: September 2014

Clinical study that aims to evaluate a new strategy using the SYNTAX II Score calculator in the functional assessment of patients with new coronary 3-vessel-disease who undergo percutaneous coronary intervention (PCI)

Condition Intervention
Heart Diseases
Cardiovascular Diseases
3 Vessel Coronary Artery Disease
Device: Coronary stent
Radiation: Multi Slice Computed Tomography
Device: instantaneous wave-free ratio
Device: Fractional flow reserve
Device: Intravascular Ultrasound

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: A Single-arm Trial to Evaluate the Effectiveness of PCI of de Novo 3-vessel Disease Applying the SYNTAX Score II With Pressure Wire Functional Assessment and IVUS Guidance, Using an Everolimus-eluting Stent With Biodegradable Abluminal Coating

Resource links provided by NLM:

Further study details as provided by ECRI bv:

Primary Outcome Measures:
  • Composite of major adverse cardiac and cerebrovascular events (MACCE) rate compared to PCI arm of SYNTAX I [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization

Secondary Outcome Measures:
  • Composite of all-cause death, cerebrovascular event (stroke), documented myocardial infarction compared to the PCI arm of SYNTAX I [ Time Frame: 1 Year ] [ Designated as safety issue: Yes ]
  • Composite of cardiovascular death, documented target-vessel myocardial infarction and repeat target lesion revascularization at 1 year follow-up compared to the PCI arm of SYNTAX I [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
  • Rates of individual components of MACCE at 1 year [ Time Frame: 1 Year ] [ Designated as safety issue: Yes ]
    MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization.

  • The composite of MACCE and its individual components of 2-5 years period of follow-up (patient reported) [ Time Frame: 2-5 Years ] [ Designated as safety issue: Yes ]
    MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization

  • Myocardial Infarction (MI) - according to Universal MI definition 2012 [ Time Frame: 1 Years ] [ Designated as safety issue: Yes ]
  • Stent Thrombosis - according to ARC definitions [ Time Frame: 1 Years ] [ Designated as safety issue: Yes ]
  • Myocardial Infarction - according to Universal MI definition 2012 [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
  • Myocardial Infarction - according to Universal MI definition 2012 [ Time Frame: 3 Years ] [ Designated as safety issue: Yes ]
  • Myocardial Infarction - according to Universal MI definition 2012 [ Time Frame: 4 Years ] [ Designated as safety issue: Yes ]
  • Myocardial Infarction - according to Universal MI definition 2012 [ Time Frame: 5 Years ] [ Designated as safety issue: Yes ]
  • Stent Thrombosis - according to ARC definitions [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
  • Stent Thrombosis - according to ARC definitions [ Time Frame: 3 Years ] [ Designated as safety issue: Yes ]
  • Stent Thrombosis - according to ARC definitions [ Time Frame: 4 Years ] [ Designated as safety issue: Yes ]
  • Stent Thrombosis - according to ARC definitions [ Time Frame: 5 Years ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • Composite of MACCE at 5 years follow-up compared to coronary artery bypass graft (CABG) arm of the SYNTAX I Trial [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    Exploratory endpoint. MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization

Estimated Enrollment: 450
Study Start Date: December 2013
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Percutaneous Coronary Intervention
All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)
Device: Coronary stent
Other Name: SYNERGY™ EES
Radiation: Multi Slice Computed Tomography
A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
Other Name: MSCT
Device: instantaneous wave-free ratio
Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
Other Name: iFR
Device: Fractional flow reserve
Pressure-derived index on physiological assessment of stenosis severity
Other Name: FFR
Device: Intravascular Ultrasound
Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
Other Name: IVUS

Detailed Description:

The purpose of the SYNTAX II Trial is to investigate the management of de-novo 3-vessel-disease in order to prospectively assess which patients would have at least comparable short and long term clinical outcomes between coronary artery bypass graft and percutaneous coronary intervention (PCI), using contemporary PCI practice. In SYNTAX II the effectiveness of a contemporary stent (designed with thinner struts, biocompatible and biodegradable polymer, and a limus based drug), the use of pressure wire assessment of lesions to allow for ischemia-driven revascularisation, intravascular ultrasound (IVUS) guidance to optimise drug eluting stent deployment, and the treatment of (chronic) total occlusion lesions with contemporary techniques, will be compared against PCI practice in the original SYNTAX trial. The proposed study would involve the SYNTAX Score II to prospectively recruit subjects on the grounds of patient safety


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with de novo 3 vessel disease


Inclusion Criteria:

  • At least 1 stenosis, angiographic, visually determined de novo lesions with more than 50 percent diameter stenosis in all 3 major epicardial territories. These are left descending coronary artery (LAD) and or side branch, proximal circumflex coronary artery (LCX) and or side branch, right descending coronary artery (RCA) and or side branch which are supplying viable myocardium without left main involvement. Patients with ostial LAD or ostial CX Medina 0,0,1 or Medina 0,1,0 may be enrolled
  • Patients with hypoplastic RCA with absence of descending posterior and presence of a lesion in the LAD and CX territories may be included in the trial as a 3 vessel disease equivalent
  • Vessel size should be at least 1.5 mm in diameter as visually assessed in diagnostic angiogram
  • Patients with

    1. stable (Canadian Cardiovascular Society Class 1, 2, 3 or 4) angina pectoris
    2. or unstable (Braunwald class) angina pectoris and ischemia
    3. or patients with atypical chest pain or those who are asymptomatic provided they have myocardial ischemia, for example treadmill exercise test, radionuclide scintigraphy, stress echocardiography
  • All anatomical SYNTAX Scores are eligible for initial screening with the SYNTAX Score II
  • Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site
  • Signed Heart Team Decision Form between local cardiologist and surgeon that the selected case meets all of the inclusion and exclusion criteria

Exclusion Criteria:

  • Under the age of 21 years
  • Known pregnancy at time of enrolment. Female of childbearing potential, and last menstruation within the last 12 months, who are not taking adequate contraceptives. Female who is breastfeeding at time of enrolment
  • Prior PCI or CABG
  • Ongoing acute myocardial infarction and enzymes (CKMB) more than 2x upper limit of normal
  • Concomitant cardiac valve disease requiring surgical therapy, reconstruction or replacement
  • Single or two-vessel disease at time of Heart Team consensus
  • Participation or planned participation in another cardiovascular clinical study before one year follow up is completed
  • Mental condition, psychiatric or organ cerebral disease, rendering the subject unable to understand the nature, scope, and possible consequences of the study or mental retardation or language barrier such that the patient is unable to give informed consent and potential for non-compliance towards the requirement in the study protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02015832

Contact: Eliane Lopes Dos Santos +31102402409 elopes@cardialysis.nl
Contact: Rob Schneijdenberg +31102062828 rschneijdenberg@cardialysis.nl

Medical Center Leeuwarden Withdrawn
Leeuwarden, Friesland, Netherlands, 8934 AD
Academisch Medical Center Recruiting
Amsterdam, Noord Holland, Netherlands, 1105 AZ
Contact: S.H. van Oortwijn    020 566 80 51    s.h.oortwijn@amc.uva.nl   
Contact: M.A. van Lavieren    020 566 80 51    m.a.vanlavieren@amc.uva.nl   
Principal Investigator: J.J. Piek, Professor         
Sint-Antonius Hospital Recruiting
Nieuwegein, Utrecht, Netherlands, 3430 EM
Contact: Maarten Jan Suttorp, MD    +31 (0)30 609 22 78    m.suttorp@antoniusziekenhuis.nl   
Principal Investigator: Maarten-Jan Suttorp, MD         
ErasmusMC Recruiting
Rotterdam, Zuid-Holland, Netherlands, 3015 GD
Contact: Mattie Lenzen    +31 (0)10 703 28 91    m.lenzen@erasmusmc.nl;   
Contact: Robert Jan van Geuns, MD    +31 (0) 10 703 28 91    r.vangeuns@erasmusmc.nl   
Principal Investigator: Nicolas van Mieghem, MD         
American Heart of Poland Recruiting
Bielsko-Biała, Poland, 43-316
Contact: Anna Turek    +33 517-262-414    a.turek@klinikiserca.pl   
Contact: Pawel Buszman, MD    +33 517-262-414    pbuszman@ka.onet.pl   
Principal Investigator: Pawel Buszman, MD         
Slaskiego Uniwersytetu Medycznego w Katowicach Gornoslaskie Centrum Not yet recruiting
Katowice, Poland
Contact: Andrzej Ochala, MD         
Principal Investigator: Andrzej Ochala, MD         
Pracownia Hemodynamiki i Angiografii II Oddzialu Klinicznego Kardiologii Not yet recruiting
Krakow, Poland
Contact: Dariusz Dudek, professor         
Principal Investigator: Dariusz Dudek, professor         
St Raphael Hospital Not yet recruiting
Krakow, Poland
Contact: Rafal Depukat, MD    +48506858175    rafdak@poczta.onet.pl   
Principal Investigator: Dariusz Dudek, Professor         
Szpital Kliniczny Recruiting
Poznan, Poland, 60583
Contact: Katarzyna Stanislawska    0048 606 837 107    kasia.stanislawska@onet.eu   
Contact: Maciej Lesiak, MD    0048 606 837 107    maciej.lesiak@skpp.edu.pl   
Principal Investigator: Maciej Lesiak, MD         
Hospital Marques de Valdecilla Recruiting
Santander, Cantabria, Spain, 39008
Contact: Javier Zueco, MD    0034 9422 027 44    jzueco@humv.es   
Principal Investigator: Javier Zueco, MD         
Complejo Asistencial Universitario de León Recruiting
Leon, Castilla y Leon, Spain, 24071
Contact: Olga Larrode    0034 987 237 683    olarrode@yahoo.es   
Contact: Amando Perez, MD    0034 987 237 683    aperez@secardiologia.es   
Principal Investigator: Amando Perez de Prado, MD         
Hospital Clinico Y Provincial Recruiting
Barcelona, Cataluna, Spain, 8025
Contact: Eva Trelliso, researchcoordinator    0034 9322 793 05    etrellis@clinic.ub.es   
Contact: Manel Sabate, MD    0034 9322 793 05    MASABATE@clinic.ub.es   
Principal Investigator: Manel Sabate, MD         
Hospital Puerta de Hierro Recruiting
Madrid, Comunidad Autonoma de Madrid, Spain, 28222
Contact: Jose Antonio Fernandez Diaz    0034 9119 174 08    joseantoniofer@gmail.com   
Contact: Javier Goicolea, MD    0034 9119 174 08    j_goicolea@hotmail.com   
Principal Investigator: Javier Goicolea, MD         
Hospital Universitario La Paz Recruiting
Madrid, Comunidad Autonoma de Madrid, Spain, 28046
Contact: Raul Moreno, MD    +34 91 727 70 00 ext 47355    raulmorenog@hotmail.com   
Principal Investigator: Raul Moreno, MD         
Hospital Clinico San Carlos Recruiting
Madrid, Comunidad Autonoma de Madrid, Spain, 28040
Contact: Javier Escaned, MD    0034 6658 79 441    escaned@secardiologia.es   
Principal Investigator: Javier Escaned, MD         
Meixoeiro Hospital Recruiting
Vigo, Galicia, Spain, 36214
Contact: Seila Diaz Costas    0034 9868 111 63    investigacion.cardioloxia.vigo@gmail.com   
Contact: Andres Iniguez, MD    0034 9868 111 63    andres.iniguez.romo@sergas.es;   
Principal Investigator: Andres Iniguez, MD         
Arrixaca University Hospital Murcia Recruiting
Murcia, Region de Murcia, Spain, 30120
Contact: Mariano Valdes, MD    0034 6296 567 31    mvch@valdeschavarri.e.telefonica.net   
Principal Investigator: Mariano Valdes, MD         
Hospital Clinico Salamanca Recruiting
Salamanca, Spain, 37007
Contact: Ignacio Cruz Gonzalez, MD    0034 6874 256 95 ext 55369    cruzgonzalez.ignacio@gmail.com   
Principal Investigator: Ignacio Cruz, MD         
CHUV Not yet recruiting
Lausanne, Switzerland, CH-1011
Contact: Nathalie Lauriers    +41 79 55 60 618    nathalie.lauriers@chuv.nl   
Contact: Erik Eeckhout, MD    +41 79 55 60 618    Eric.Eeckhout@chuv.ch   
Principal Investigator: Erik Eeckhout, MD         
United Kingdom
Belfast Health & Social Care Trust Recruiting
Belfast, County Antrim, United Kingdom, BT13 1FD
Contact: Bernie Smith    0044 28 9063 2221    bernie.smith@belfasttrust.hscni.net   
Contact: Simon Walsh, MD    0044 28 9063 2221    simon.walsh@belfasttrust.hscni.net   
Principal Investigator: Simon Walsh, MD         
John Radcliffe Infirmary Oxford II Recruiting
Oxford, Oxfordshire, United Kingdom, OX3 9DU
Contact: Bernadette Moreby, study coordinator    +44 (0) 1865    bernadette.moreby@ouh.nhs.uk   
Contact: Adrian Banning, MD    +44 1865 22 89 34    adrian.banning@ouh.nhs.uk   
Principal Investigator: Adrian Banning, MD         
Papworth Hospital, Papworth Hospital Recruiting
Cambridge, United Kingdom, CB23 3RE
Contact: Sallyanne Meakins    +44 01480 364980    Sallyanne.meakins@papworth.nhs.uk   
Contact: Nick West, MD    +44 01480 364504    Nick.West@papworth.nhs.uk   
Principal Investigator: Nick West, MD         
Royal Infirmary of Edinburgh Recruiting
Edinburgh, United Kingdom, EH16 4SA
Contact: Belinda Rif, study coordinator    +44 0131 242 1886    belinda.rif@nhslothian.scot.nhs.uk   
Contact: Neal Uren, MD    +44 0131 242 1046    neal.uren@nhslothian.scot.nhs.uk   
Principal Investigator: Neal Uren, MD         
Liverpool Heart and Chest Hospital Recruiting
Liverpool, United Kingdom, L14 3PE
Contact: Clare Appleby, MD    +44 01510600 1887    Clare.Appleby@lhch.nhs.uk   
Principal Investigator: Clare Appleby, MD         
The London Chest Hospital Withdrawn
London, United Kingdom, E2 9JX
St Thomas Hospital Not yet recruiting
London, United Kingdom, SE5 9RS
Contact: Jayne Damm    +44 20 7188 9484    jayne.damm@gsstt.nhs.uk   
Contact: Simon Redwood, MD    +44 0207 1888 6271    simon.redwood@gstt.nhs.uk   
Principal Investigator: Simon Redwood, MD         
Imperial College Healthcare NHS Trust Recruiting
London, United Kingdom, W12 OHS
Contact: Rasha Al-Lamee    0044 797 183 1328    "Rasha.Al-Lamee@imperial.nhs.uk   
Contact: Justin Davies, MD    0044 797 183 1328    justindavies@heart123.com   
Principal Investigator: Justin Davies, MD         
Manchester Royal Infirmary Recruiting
Manchester, United Kingdom, M13 9WL
Contact: Sarah Evans    +44 (0) 161 276 3336    Sarah.evansmhc@cmft.nhs.uk   
Contact: Faz Fath Ordoubadi, MD    +44 (0) 161 276 5770    Farzin.Fath-ordoubadi@cmft.nhs.uk   
Principal Investigator: Faz Fath Ordoubadi, MD         
Freeman Hospital Recruiting
Newcastle upon Tyne, United Kingdom, NE7 7DN
Contact: Samantha Jones    +44 (0)191 2138272    samantha.jones@nuth.nhs.uk   
Contact: Azfar Zaman, MD    +44 (0)191 213 72 77    azfar.zaman@nuth.nhs.uk   
Principal Investigator: Azfar Zaman, MD         
Sponsors and Collaborators
Boston Scientific Corporation
Volcano Corporation
Study Chair: Patrick Serruys, Prof. MD. Thoraxcenter, Erasmus, The Netherlands
Principal Investigator: Javier Escaned, MD Hospital San Carlos Madrid, Spain
Principal Investigator: Adrian Banning, MD John Radcliffe Hospital, Oxford, United Kingdom
Study Director: Gerrit-Anne van Es ECRI, The Netherlands
Principal Investigator: Arie-Pieter Kappetein, MD Thorax center, Erasmus, The Netherlands
Principal Investigator: David Taggart, MD John Radcliffe Hospital, Oxford. United Kingdom
Principal Investigator: Vasim Farooq, MD Manchester Royal Infirmary, United Kingdom
  More Information

No publications provided

Responsible Party: ECRI bv
ClinicalTrials.gov Identifier: NCT02015832     History of Changes
Other Study ID Numbers: ECRI-002
Study First Received: December 13, 2013
Last Updated: September 14, 2014
Health Authority: Netherlands: Medical Ethics Review Committee (METC)
Spain: Ethics Committee
Switzerland: Ethikkommission
United Kingdom: Research Ethics Committee

Keywords provided by ECRI bv:
Pressure wires
instantaneous wave-free ratio
fractional flow reserve
intravascular ultrasound
Drug eluting stents
multi slice computed tomography

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Artery Disease
Coronary Disease
Heart Diseases
Myocardial Ischemia
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 23, 2014